Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ABT-700 · 1 trial · 1 indication
Evaluation of vital signs, clinical lab testing, physical exams and adverse event monitoring
Pharmacokinetic profile of ABT-700 analyzed from blood samples
| Arm | Type | Description |
|---|---|---|
| Cohort A | EXPERIMENTAL | ABT-700 will be administered by intravenous infusion at escalating dose levels in 21-day dosing cycles. Additional subjects will be enrolled in an expansion cohort that will further evaluate ABT-700. |
| Cohort B | EXPERIMENTAL | ABT-700 plus docetaxel. |
| Cohort C | EXPERIMENTAL | ABT-700 plus FOLFIRI/cetuximab |
| Cohort D | EXPERIMENTAL | ABT-700 plus erlotinib |
| Name | Type | Description |
|---|---|---|
| ABT-700 | DRUG | ABT-700 will be administered by intravenous infusion at escalating dose levels on day 1 in 21-day dosing cycles. Additional subjects will be enrolled in an dose expansion cohort that will further evaluate ABT-700. |
| docetaxel | DRUG | Docetaxel will be administered by intravenous infusion on Day 1 in 21-day dosing cycles. |
| FOLFIRI | DRUG | 5-fluorouracil, Folinic acid and Irinotecan will be administered by intravenous infusion on Day 1 and 15 in 28-day dosing cycles. |
| cetuximab | DRUG | Cetuximab will be administered by intravenous infusion weekly. |
| erlotinib | DRUG | Erlotinib will be taken orally daily. |
Inclusion Criteria: * Subject with advanced solid tumors; Dose-expansion: evidence for MET gene amplification. * Subject must have disease: a) that is not amenable to surgical resection, or b) that has progressed or recurred despite standard therapy, or c) that has failed to respond to standard the...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 3 | PHASE2 | Pembrolizumab, Gardasil 9 |
| Incyte Corporation | INCY | 1 | PHASE2 | Retifanlimab |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115 |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | Aldesleukin |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |
ABT-700 is an investigational small molecule being studied for the treatment of advanced solid tumors. It was evaluated in a Phase 1 clinical trial in adult patients with advanced solid tumors. It is not an approved therapy and remains in clinical development.
ABT-700 is being developed by AbbVie Inc., which trades on the New York Stock Exchange under the ticker ABBV. AbbVie sponsored the Phase 1 study of ABT-700 in advanced solid tumors.
ABT-700 is in Phase 1 development. One Phase 1 trial, NCT01472016, has been completed, and no active trials are currently listed. ABT-700 is investigational and has not been approved for any indication.
ABT-700 has been studied in one clinical trial, NCT01472016, titled Study of ABT-700 in Subjects With Advanced Solid Tumors. The Phase 1 trial enrolled 74 adults with advanced solid tumors and is now completed.
No. The Phase 1 trial of ABT-700, NCT01472016, was not randomized and was not double blinded. It used a controlled design and enrolled 74 participants aged 18 years and older with advanced solid tumors.
Yes. The clinical development of ABT-700 in advanced solid tumors was biomarker selected, meaning trial enrollment was guided by a biomarker rather than an unselected patient population.